The therapy becomes an option for moderate-to-severe plaque psoriasis in certain adults
Bristol Myers Squibb (BMS) has announced that the National Institute for Health and Care Excellence (NICE) has recommended Sotyktu – also known as deucravacitinib – for use across the NHS in England.
The therapy is a once-daily oral tablet, for use on the NHS in England as a treatment option among certain adults with moderate-to-severe plaque psoriasis. This guidance ensures that deucravacitinib will be available to patients if the psoriasis area and severity index (PASI) is ten or more and the dermatology life quality index (DLQI) is greater than ten…
